Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients - Scorecard - MDSpire

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

  • By

  • May Ee Png

  • Victoria Harris

  • Ly-Mee Yu

  • Paul Little

  • F. D. Richard Hobbs

  • Christopher C. Butler

  • Stavros Petrou

  • PANORAMIC Trial Collaborative Group

  • Oghenekome A Gbinigie

  • Najib M Rahman

  • Gail Hayward

  • Duncan B Richards

  • Jienchi Dorward

  • David M Lowe

  • Joseph F Standing

  • Judith Breuer

  • Saye Khoo

  • Kerenza Hood

  • Jonathan S Nguyen-Van-Tam

  • Mahendra G Patel

  • Benjamin R Saville

  • Joe Marion

  • Nick Francis

  • Nicholas P B Thomas

  • Philip Evans

  • Melissa Dobson

  • Jane Holmes

  • Mark Lown

  • Oliver van Hecke

  • Michelle A Detry

  • Christina T Saunders

  • Mark Fitzgerald

  • Nicholas S Berry

  • Sam Mort

  • Bhautesh D Jani

  • Nigel D Hart

  • Haroon Ahmed

  • Daniel Butler

  • Micheal McKenna

  • Lucy Cureton

  • Meena Patil

  • Monique Andersson

  • Clare Bateman

  • Jennifer C Davies

  • Andrew Ustianowski

  • Andrew Carson Stevens

  • May 6, 2026

  • 0 min

Share

Clinical Scorecard: Cost-Effectiveness Analysis of Oral Nirmatrelvir-Ritonavir for Treating COVID-19 in High-Risk Outpatients

At a Glance

CategoryDetail
ConditionCOVID-19 in high-risk outpatients
Key MechanismsNirmatrelvir-ritonavir reduces risk of hospitalization and death when initiated early.
Target PopulationAdults aged 50 years or older or adults aged 18 to 49 years with specified comorbidities.
Care SettingCommunity-based treatment in the UK.

Key Highlights

  • Nirmatrelvir-ritonavir reduced hospitalization or death risk by 89% when started within 5 days of symptom onset.
  • Cost-effective across high-income and middle-income countries during the Omicron wave.
  • Effectiveness varies by vaccination status, with mixed findings on cost-effectiveness.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of COVID-19 in high-risk patients.

Management

  • Initiate nirmatrelvir-ritonavir within 5 days of symptom onset.

Monitoring & Follow-up

  • Monitor health-related quality of life and resource use.

Risks

  • Consider underlying severe conditions in treatment decisions.

Patient & Prescribing Data

High-risk outpatients, including older adults and those with comorbidities.

Oral nirmatrelvir 300 mg with ritonavir 100 mg taken twice daily for 5 days.

Clinical Best Practices

  • Conduct economic evaluations alongside clinical trials for accurate cost-effectiveness data.
  • Utilize comprehensive data collection methods for resource use and health outcomes.

Related Resources & Content

Original Source(s)

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

  • by May Ee Png, Victoria Harris, Ly-Mee Yu, Paul Little, F. D. Richard Hobbs, Christopher C. Butler, Stavros Petrou, PANORAMIC Trial Collaborative Group, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Kerenza Hood, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Joe Marion, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, Jane Holmes, Mark Lown, Oliver van Hecke, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Sam Mort, Bhautesh D Jani, Nigel D Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Lucy Cureton, Meena Patil, Monique Andersson, Clare Bateman, Jennifer C Davies, Andrew Ustianowski, Andrew Carson Stevens

  • May 6, 2026

Related Content

Permanent hypoparathyroidism following SARS-CoV-2 infection: a case report with two-year follow-up and literature review

Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany

Recent COVID-19 Shot Linked to Less Spread

Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.